Business Description
Xintela AB
ISIN : SE0007756903
Total Employee Number:
11Compare
Compare
Traded in other countries / regions
XINT.Sweden1XT.Germany IPO Date
2016-03-22Description
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | -1.2 | |||||
Debt-to-Equity | -1.14 | |||||
Debt-to-EBITDA | -0.42 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -52.65 | |||||
Beneish M-Score | -5.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.9 | |||||
3-Year EPS without NRI Growth Rate | 42.5 | |||||
3-Year FCF Growth Rate | 47.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.51 | |||||
9-Day RSI | 48.91 | |||||
14-Day RSI | 47.3 | |||||
3-1 Month Momentum % | -15.19 | |||||
6-1 Month Momentum % | -21.84 | |||||
12-1 Month Momentum % | -39.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.45 | |||||
Quick Ratio | 0.45 | |||||
Cash Ratio | 0.3 | |||||
Days Sales Outstanding | 40.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.7 | |||||
Shareholder Yield % | -24.18 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1848.94 | |||||
Net Margin % | -1931.03 | |||||
EBITDA Margin % | -1825.92 | |||||
FCF Margin % | -1717.87 | |||||
OCF Margin % | -1715.16 | |||||
ROA % | -297.26 | |||||
ROIC % | -160.33 | |||||
3-Year ROIIC % | 118.52 | |||||
ROC (Joel Greenblatt) % | -10860.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 100.5 | |||||
EV-to-EBIT | -3.6 | |||||
EV-to-EBITDA | -3.64 | |||||
EV-to-Revenue | 66.73 | |||||
EV-to-FCF | -4.45 | |||||
Earnings Yield (Greenblatt) % | -27.71 | |||||
FCF Yield % | -25.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xintela AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 2.585 | ||
| EPS (TTM) (kr) | -0.07 | ||
| Beta | 0.5657 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.46 | ||
| Volatility % | 41.8 | ||
| 14-Day RSI | 47.3 | ||
| 14-Day ATR (kr) | 0.022183 | ||
| 20-Day SMA (kr) | 0.201175 | ||
| 12-1 Month Momentum % | -39.41 | ||
| 52-Week Range (kr) | 0.161 - 0.531121 | ||
| Shares Outstanding (Mil) | 861.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xintela AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xintela AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 55 days | ||
| General meeting for 2025 | 2026-06-22 09:00 | 0.19 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-29 | 0.24 (+0.42%) | ||
| Annual report for 2025 | 2026-04-30 | 0.24 (-3.64%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-28 | 0.28 (+0.73%) | ||
| Third quarter earnings results for 2025 | 2025-11-21 | 0.26 (+4.86%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 0.37 (+0.54%) | ||
| General meeting for 2024 | 2025-06-13 09:00 | 0.44 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-23 | 0.48 (-2.04%) |
Show
Entries
Xintela AB Frequently Asked Questions
What is Xintela AB(OSTO:XINT)'s stock price today?
The current price of OSTO:XINT is kr0.20. The 52 week high of OSTO:XINT is kr0.53 and 52 week low is kr0.16.
When is next earnings date of Xintela AB(OSTO:XINT)?
The next earnings date of Xintela AB(OSTO:XINT) is 2026-08-28 Est..
Does Xintela AB(OSTO:XINT) pay dividends? If so, how much?
Xintela AB(OSTO:XINT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Xintela AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers